CMT-3 nanoformulations for systemic and local administration for inflammation control

Background:

CMT-3 is a potent anti-inflammatory compound with promising therapeutic potential; however, its poor water solubility significantly restricts its effectiveness when administered orally. This limitation poses a considerable challenge in treating serious inflammatory conditions such as acute respiratory distress syndrome (ARDS) and lung injury, where efficient and targeted drug delivery is critical. To overcome these challenges, researchers sought to develop a new formulation that would improve CMT-3’s solubility and enable more effective administration methods suitable for acute and systemic inflammation control.

Technology Overview:

This invention involves the creation of telodendrimer-based nanoformulations that encapsulate the CMT-3 compound, drastically enhancing its water solubility and bioavailability. Telodendrimers are highly branched, nanoscale polymers known for their ability to carry and release therapeutic agents efficiently. By integrating CMT-3 within these nano-carriers, the formulation permits intravenous or inhalation delivery routes, which facilitate rapid and targeted treatment of both systemic inflammation and localized lung injury, particularly in conditions like ARDS. The nanoformulation allows for controlled drug release, improved stability of CMT-3 in biological environments, and enhanced penetration into inflamed tissues. This novel delivery system uniquely addresses the shortcomings of oral administration, such as poor absorption and reduced therapeutic levels, thereby ensuring higher efficacy in critical care scenarios. Furthermore, the technology builds upon existing telodendrimer intellectual property but applies it in a new context specifically for inflammatory lung diseases, marking a significant advancement in drug delivery systems.

Advantages:

•    Improved water solubility of CMT-3 enables more effective drug administration and absorption.
•    Allows for intravenous and inhalation routes, offering flexible and targeted delivery options.
•    Enhanced bioavailability leads to higher therapeutic effectiveness in controlling inflammation.
•    Controlled release and increased stability promote sustained anti-inflammatory effects.
•    Specifically designed for acute inflammatory conditions such as ARDS and lung injury, addressing unmet medical needs.
•    Novel use of telodendrimer technology tailored for systemic and local inflammation management.

Applications:

•    Treatment of acute respiratory distress syndrome (ARDS) through intravenous or inhalation delivery.
•    Management of lung injuries characterized by severe inflammation.
•    Systemic control of inflammation in critical illnesses requiring rapid and effective intervention.
•    Potential use in other inflammatory diseases where improved drug solubility and bioavailability are advantageous.

Intellectual Property Summary:

Patent application filed

Stage of Development:

TRL 3 – Experimental Proof of Concept

Licensing Status:

This technology is available for licensing.